New Jersey, NJ, Jan. 16, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global diphtheria, pertussis, and tetanus (DTaP) vaccine market is expected to grow from USD 2.97 Billion in 2018 to USD 5.07 Billion by 2026, at a CAGR of 6.91% during the forecast period from 2019-2026. Growing incidence of diphtheria, tetanus and pertussis coupled with rising worldwide governmental support for the vaccination programs are anticipated to drive the global DTaP vaccine market.
Diphtheria, pertussis, and tetanus (DTaP) vaccine is administered for immunizing the humans against the three infectious diseases viz diphtheria, tetanus, and pertussis. DTaP vaccine is are administered either in childhood or middle age to produce the acquired immunity against diphtheria, pertussis, and tetanus. Growing incidence of diphtheria, tetanus and pertussis coupled with rising worldwide governmental support for the vaccination programs are anticipated to drive the global DTaP vaccine market.
DOWNLOAD FREE SAMPLE REPORT AT https://www.fiormarkets.com/report-detail/407138/request-sample
Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market Key Findings:
- Even though the factors such as growing demand for DTaP vaccine, rising Incidences of diphtheria, tetanus and pertussis as well as rising awareness pertaining the advantages of inoculation are driving the global diphtheria, pertussis, and tetanus (DTaP) vaccine market. The scattered incidences of vaccines causing injuries and stringent regulatory approval process are expected to restrain the market growth.
- Increasing investment on research and development activities, growing government and institutional support for the vaccination programs, and growing demand from the emerging economies are the expected to develop new opportunities for the global diphtheria, pertussis, and tetanus (DTaP) vaccine market in upcoming years.
- The product type segment consists of Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. Kinrix is a combined diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated poliomyelitis vaccine (DTaP-IPV). Clinical trials have shown Kinrix to be immunogenic in 4-6-year-old children, with a safety profile comparable with that of separate DTaP and IPV vaccination. As a result the Kinrix segment is anticipated to grow at the highest CAGR of 8.89% over the forecast period. In addition, Kinrix was approved by FDA for use in children who are 4 to 6 years of age to protect against diphtheria, tetanus, pertussis, and polio. The KINRIX is to be administered as a 0.5-mL dose by intramuscular injection. It is used for the fifth dose in the DTaP immunization series and the fourth dose in 27 the IPV immunization series in children 4 through 6 years of age.
- Disease type is segmented into diphtheria, tetanus, and pertussis. The pertussis segment led the global DTaP vaccine market with the revenue of USD 1.44 billion in 2018. Growing incidence of childhood pertussis was the primary driving factor behind this increased market share. In many people, pertussis is marked by a severe hacking cough followed by a high-pitched intake of breath that sounds like "whoop”. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe and cause serious illness in babies, children, teens, and adults. Pertussis is an infection of the respiratory system caused by the bacterium Bordetella pertussis (or B. pertussis).
- The end user segment is divided into hospitals, clinics and vaccination centers. There has been global push for bringing more and more children under the vaccination umbrella. World Bank, local governments along with CSR foundations taking forward this cause. Thus, the vaccination centers segment is expected to grow at the highest CAG of 8.98% over the forecast period. The vaccination centers contained the large storage of vaccines that helps to protects against whooping cough, diphtheria, and tetanus (for infants and children) Tdap vaccine
- The regions analyzed for the global diphtheria, pertussis, and tetanus (DTaP) vaccine market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. The North America region emerged as the largest market for the DTaP vaccine with a 39.56% share of market revenue in 2018.
- Well-developed healthcare facilities, high level of awareness pertaining the benefits of vaccination along with strong institutional support led the North America region to dominate the global diphtheria, pertussis, and tetanus (DTaP) vaccine market in 2018.
- The Asia Pacific region is expected to grow at the highest CAGR of 9.02% over the forecast period. This increased grow can attributed to huge number of infant population and rising awareness about the benefits of vaccination is anticipated to drive the regional growth of Asia Pacific region in the global diphtheria, pertussis, and tetanus (DTaP) vaccine market during the forecast period.
- For instance, in 2018, Panacea BiotecNSE has signed two long-term agreements with Serum Institute of India (SII) and its wholly-owned subsidiary to manufacture and sell a type of hexavalent vaccine. The vaccine is a combination of six antigens to protect against six dreaded diseases - Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type B and Polio.
- For instance in 2016, Sanofi Pasteur launched the paediatric 6-in-1 vaccine in India. This ready-to-use fully liquid vaccine provides protection against diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenza B and hepatitis B.
- Key players in global diphtheria, pertussis, and tetanus (DTaP) vaccine market are GlaxoSmithKline, Sanofi Pasteur, Protein Sciences Corporation, Novartis AG, Merch Sharp & Dohme Corp., Pfizer Inc., Astellas Pharma US, Sanofi Aventis, AstraZeneca, and Emergent Biosolution Inc. among others.
Browse full report with TOC at https://www.fiormarkets.com/report/diphtheria-pertussis-and-tetanus-dtap-vaccine-market-by-407138.html
All the segments have been analysed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment.
This study forecasts revenue growth and volume at global, regional, and country levels from 2016 to 2026. Fior Markets has segmented global diphtheria, pertussis, and tetanus (DTaP) vaccine market on the basis of below-mentioned segments:
Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market by Product Type:
- Daptacel
- Infanrix
- Kinrix
- Pediarix
- Pentacel
- Quaracel
Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market by Disease Type:
- Diphtheria
- Tetanus
- Pertussis
Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market by End User:
- Hospitals
- Clinics
- Vaccination Centers
Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market by Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
For Instant Purchase: https://www.fiormarkets.com/checkout.html?reportid=407138&type=single
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
About Fior Markets
Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients’ objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.
Contact Us
Avinash D
Head of Business Development
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com
To know more market research reports and industry analysis, visit our associate website: https://www.marketresearchplace.com
Related Reports
Global Needle-Free Drug Delivery Devices Market - https://www.fiormarkets.com/report/global-needle-free-drug-delivery-devices-market-by-technology-376045.html
Global Extracorporeal CO2 Removal Market - https://www.fiormarkets.com/report/global-extracorporeal-co2-removal-market-by-type-extracorporeal-376046.html
Global Active Pharmaceutical Ingredient/ API Market - https://www.fiormarkets.com/report/global-active-pharmaceutical-ingredient-api-market-by-type-376047.html
Global Anatomic Pathology Market - https://www.fiormarkets.com/report/global-anatomic-pathology-market-by-product-service-376048.html